Zimmermann Richard
Medical Biochemistry and Molecular Biology, Saarland University, 66421 Homburg, Germany.
Int J Mol Sci. 2025 Sep 10;26(18):8823. doi: 10.3390/ijms26188823.
In human cells, the biogenesis of membrane proteins, which account for one quarter of polypeptides and sixty percent of human drug targets, is initiated at the membrane of the endoplasmic reticulum (ER). This process involves N-terminal signal peptides or transmembrane helices in the membrane protein precursors. Over one hundred proteins enable membrane-targeting and -insertion of the precursors as well as their folding and covalent modifications. Four targeting pathways to the Sec61 channel in the ER membrane with their effectors and three cooperating or independent membrane protein-insertases have been identified. We combined knock-down of individual components of these pathways and insertases in HeLa cells with label-free quantitative mass spectrometric analysis of the proteomes. Differential protein abundance analysis in comparison to control cells was employed to identify clients of components involved in the targeting or membrane insertion of precursors. Alternatively, knock-out cells or relevant patient fibroblasts were employed. The features of the client polypeptides were characterized to identify the client types of the different components and, ideally, their rules of engagement. In this review/article-hybrid, the focus is on global lessons from and limitations of the proteomic approach in answering the cell biological question, as well as on new aspects, such as N-terminal acetylation of membrane protein precursors.
在人类细胞中,膜蛋白的生物合成始于内质网(ER)膜,膜蛋白占多肽的四分之一,是人类药物靶点的60%。这一过程涉及膜蛋白前体中的N端信号肽或跨膜螺旋。超过一百种蛋白质可实现前体的膜靶向和插入以及它们的折叠和共价修饰。已确定了四种通向ER膜中Sec61通道的靶向途径及其效应器,以及三种协同或独立的膜蛋白插入酶。我们将HeLa细胞中这些途径和插入酶的各个组分的敲低与蛋白质组的无标记定量质谱分析相结合。通过与对照细胞进行差异蛋白质丰度分析,以鉴定参与前体靶向或膜插入的组分的底物。或者,使用基因敲除细胞或相关患者的成纤维细胞。对底物多肽的特征进行表征,以确定不同组分的底物类型,理想情况下,确定它们的作用规则。在这篇综述/文章混合型文章中,重点是蛋白质组学方法在回答细胞生物学问题方面的整体经验教训和局限性,以及新的方面,如膜蛋白前体的N端乙酰化。